TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Here we show that activation of p53, in both chronic and blast phases of CML, disables quiescent LSC self-renewal on a TKI background and reduces the level of residual LSC in PDX models - even when TKI treatment is initiated prior to p53 activation.